Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Foscenvivint - PRISM Pharma Co

Next Previous
Drug Profile

Foscenvivint - PRISM Pharma Co

Alternative Names: CBP-beta catenin inhibitor; ICG-001; OP-724; PRI-724

Latest Information Update: 23 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PRISM BioLab; University of Southern California
  • Developer Ohara Pharmaceutical; PRISM Pharma Co; Syneos Health; Tokyo Metropolitan Komagome Hospital
  • Class Antifibrotics; Antineoplastics; Pyrazines; Quinolines; Small molecules; Triazines
  • Mechanism of Action Beta catenin inhibitors; CREB-binding protein inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cirrhosis
  • Preclinical Hepatic fibrosis
  • No development reported Primary biliary cirrhosis; Prostate cancer
  • Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Pancreatic cancer; Solid tumours

Most Recent Events

  • 05 Aug 2026 Ohara Pharmaceutical and Japan Agency for Medical Research and Development initiates a phase I trial in Liver cirrhosis in Japan (IV) (NCT07681089)
  • 07 Jul 2026 Ohara Pharmaceutical and Japan Agency for Medical Research and Development plans a phase II trial for Liver cirrhosis in Japan (IV, Infusion) (NCT07681089)
  • 28 May 2026 No recent reports of development identified for preclinical development in Prostate-cancer in Japan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top